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ABSTRAK 
Penemuan projekl Abstrak 
(Perlu disediakan makluman di antara 100-200 perkataan di dalam 
Bahasa Malaysia dan Bahasa lnggeris, ini kemudiannya akan 
dimuatkan ke dalam laporan Tahunan Bahagian Penyelidikan dan 
Pembangunan sebagai satu cara untuk menyampaikan dapatan projek 
tuanlpuan kepada pihak Universiti.) 
Satu kajian prospektif rambang terkawal telah dijalankan untuk membandingkan kesan 
2 jenis rawatan penggantian fungsi ginjal berterusan (CRRT), iaitu venovenous 
hemofiltrasi berterusan (CVVH) dan venovenous hemodialisis berterusan (CVVHD) di 
kalangan pesakit-pesakit yang tenat dengan kegagalan ginjal akut di dalam unit rawatan 
rapi (ICU) di Hospital Selayang dan Hospital Kuala Lumpur. Tanda-tanda klinikal 
penting, jumlah urin dan keputusan biokimia dicatit setiap hari semasa rawatan 
dijalankan. Tempoh rawatan CRRT dan tempoh berada di ICU, tahap pemulihan ginjal 
dan status hidup pesakit semasa discaj dari ICU juga direkodkan. Serum untuk analisa 
sitokin (IL-6 dan 1NF-a) diambil pada masa 0 dan 24 jam rawatan CRRT. Dalam 
tempoh 28 bulan (September 2001 hingga Disember 2003), sejumlah 20 orang pesakit 
telah diselidik. Data demografi, aspek klinikal dan data makmal adalah sebanding di 
antara kedua-dua kumpulan rawatan. Peningkatan TNF-a adalah 35.6% berbanding 
173.0% dan penurunan IL-6 adalah 48.8% berbanding 18.0% di kalangan pesakit 
CVVH dan CVVHD. Kadar kematian secara keseluruhan adalah 85%. Tempoh berada 
di ICU, peratus pemulihan lengkap ginjal dan kadar kematian untuk pesakit-pesakit 
CVVH berbanding CVVHD adalah 16 hari berbanding 8 hari (p = 0.16), 11.8% 
berbanding 9.1% (p = 1.0) dan 77.7% berbanding 90.9% (p = 0.57). Kesimpulannya, di 
kalangan pesakit-pesakit rawatan CVVH, profil perubahan tahap sitokin adalah lebih 
baik namun kesan klinikal rawatan CVVH dan CVVHD adalah sama. 
ABSTRACT 
A prospective randomized controlled study was performed to compare the effect of 2 
modalities of continuous renal replacement therapy (CRRT) i.e. continuous venovenous 
haemofiltration (CVVH) versus continuous venovenous haemodialysis (CVVHD) on 
the clinical outcome in critically ill patients with acute renal failure in the intensive care 
units in Hospital Selayang and Hospital Kuala Lumpur. Patients' vital signs, urine 
volume and biochemical variables were recorded daily while on treatment. The 
duration of CRRT treatment and ICU stay, extent of renal recovery and survival status 
at discharge from ICU were also recorded. Serum for cytokines assay {IL-6 and TNF-
a) were taken at 0 hour and 24 hours ofCRRT treatment. Over a period of28 months 
(September 2001 till December 2003), a total of20 patients were included in the study. 
Patients' demographic, clinical features and laboratory data were comparable between 
the 2 treatment groups. The increase of TNF- a was 35.6% versus 173.0o/o and drop in 
IL-6 was 48.8% versus 18.0% in patients treated with CVVH and CVVHD 
respectively. The overall mortality rate was 85%. The duration of ICU stay, % of 
complete renal recovery and death rates for CVVH compared to CVVHD patients were 
16.0 days versus 8.0 days (p = 0.16), 11.1% versus 9.1% (p = 1.0) and 77.7% versus 
90.9% (p = 0.57) respectively. In conclusion, patients treated with CVVH had more 
favourable changes in cytokines level but the clinical outcomes were similar between 
CVVH and CVVHD treated groups. 
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ABSTRACT 
Introduction : Acute renal failure occurs frequently among critically ill patients in the 
Intensive Care Unit (ICU) and carries significant mortality: Continuous renal replacement 
therapy (CRRn has been favoured to conventional intermittent haemodialysis in such patients 
predominantly because of better haemodynamic stability. However no data is available on 
which modality of CRR T has better impact on patient's outcome. 
Objectives: To compare the impact of two forms of CRRT i.e. continuous venovenous 
haemofiltration (CVVH) versus continuous venovenous haemodialysis (~VVHD) on the 
following parameters: (i) changes in inflammatory cytokines (IL-6 and TNF-a}, (ii) duration of 
survival in ICU, (iii) renal recovery, and (iv) patient's outcome. 
Method : A prospective randomized controlled trial was performed on critically ill patients 
who developed acute renal failure (ARF) in intensive care unit (ICU) in Hospital Selayang and 
Hospital Kuala Lumpur, Malaysia. At enrolment, patient's demographic data, clinical 
conditions and SAPS II score were recorded. Patient's vital signs, urine volume and 
biochemical variables were recorded daily. Serum for cytokines were taken at 0 and 24 hours of 
CRRT treatment. 
Results : Over a period of 28 months (September 2001 till December 2003}, a total of 20 
patients were included in the study. Patient's demographic and clinical background were 
comparable between the two treatment groups.. There were no statistically significant 
differences in the laboratory results and vital signs. The increase of TNF-a was 35.6% versus 
173.0% and drop in IL-6 was 48.8% versus 18.0% in patients treated with CVVH and CVVHD 
respectively. The duration of ICU stay, % of complete renal recovery and death rates for 
CVVH compared to CVVHD patients were 16.0 days versus 8.0 days (p = 0.16}, 11.1% versus 
9.1% (p = 1.0) and 77.7% versus 90.9% (p = 0.57) respectively. 
Conclusion : Patients treated with CVVH had a more favourable changes in inflammatory 
cytokines level but the clinical outcome (ICU stay, renal recovery and death rates) were similar 
between CVVH and CVVHD treated groups. 
Keywords: Acute renal failure, venovenous haemodialysis, haemofiltration, cytokines 
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• 
0 
INTRODUCTION 
Acute renal failure (ARF) occurs frequently in critically ill patients in intensive 
care.1•2 It is most often a multifactorial clinical syndrome characterized by acute, but 
potentially reversible reduction in renal excretory function. If pre renal causes are 
excluded, ARF is mostly caused by a systemic disturbance such as septicaemia, 
pancreatitis and bums and very often it forms part of the multiple organ 
failure/dysfunction syndrome (MODS). Such patients are critically ill and they usually 
require various pharmacological and life-support treatments. Over several decades, the 
ntortality of patients with ARF appear to have remained unchanged despite advances in 
supportive care.2 This has been attributed to the changes in patient demographics. 
Patient age has increased, 3 illness severity has worsened, 4 and the causes of renal 
failure in young adults associated with a good outcome (predominantly obstetric 
complications and trauma) have become progressively less common? The primary aim 
of renal replacement therapy in these circumstances is to achieve adequate correction of 
homeostatic disorders with good clinical tolerance. Intermittent haemodialysis and 
peritoneal dialysis have some limitations in efficiency and clinical tolerance.5-6 
Continuous renal replacement therapy (CRRT) is increasingly being used to treat ARF 
in critically ill patients.8 The advantages of continuous treatments are steady 
biochemical correction, slow continuous fluid removal, and excellent cardiovascular 
stability.7-9 Despite these advantages, there are few data to indicate a survival advantage 
from continuous treatment. In a recent review article, Forni and Hilton suggested a 
substantial improvement in survival coincident with the introduction of continuous · 
haemofiltration in their experience, despite similar severity of illness. 10 
For more than 20 years, the continuous techniques of renal replacement therapy 
(CRRT) have acquired a well-established role in intensive care medicine, however the 
most appropriate mode of CRRT is yet to be defined. 11 Furthermore, there is no 
• 
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consensus on adequate treatment dose or on the impact of dose delivery on outcome. In 
a recent randomized controlled trial, Ronco et al 12 found that increasing the rate of 
plasma water exchange rate from 1.5 literslh to approximately 2.5 literslh reduced 
mortality in ICU patients with multiorgan failure treated with CVVH by 30%. This is 
the first randomized controlled trial which demonstrates that a modulation of a blood 
purification therapy decreases mortality in MODS with ARF. The findings of this trial 
have tremendous clinical and biological implications. Firstly, they demonstrate that 
extracorporeal blood purification therapy (EBPT) can affect mortality in a subset of 
critically ill patients. Secondly, they demonstrate that we need to explore that correct 
dose for all EBPT before we dismiss its clinical value. 
As for the impact of modality selection on patient outcome, there are still no 
data comparing patient outcomes for patients treated with continuous haemofiltration, 
continuous haemodialysis or continuous haemodiafiltration. Based on the available 
data, no recommendations regarding the use of predominantly convective therapies as 
compared to diffusive therapies can be made. Efficiency of removal of low molecular 
weight solutes is similar with convection and diffusion. Efficiency of middle and high 
molecular weight solute removal is greater with convective therapies, 13 however data 
do not exist on the clinical implications of this enhanced solute removal. We undertook 
a prospective randomized controlled study to compare the effect of convective and 
diffusive therapy (CVVH versus CVVHD) on the clinical outcome in critically ill 
patients with ARF. The doses of dialysate and ultrafiltration rates were standardized to 
achieve equal urea clearance rate and the primary aim of the study was to compare both . 
patient and renal outcomes. Duration of survival in ICU and changes in the blood 
cytokines profile were also studied. 
.. 
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OBJECTIVES 
Primary Objectives 
To compare the impact of two forms of continuous renal replacement therapies 
(CRRT), continuous venovenous haemofiltration (CVVH) versus continuous 
venovenous haemodialysis (CVVHD) on patient and renal outcome in critically ill 
patients with acute renal failure. 
Secondary Objectives 
To compare the duration of survival in ICU in both study groups and to compare the 
changes in inflammatory cytokine profile (IL-6 and. TNF-a). 
Materials and Methods . 
Design: Prospective randomized controlled trial. 
Inclusion Criteria 
I. Critically ill patients on ventilatory support in intensive-care unit or coronary 
care unit with 
2. Acute renal failure, defined by a sudden rise in serum creatinine concentration 
to over 2.3 mg/dL ( 200 umol!L) in patients with prior normal renal function, 
and/or a rise by more than 2.3 mg/dL ( 200 umol/L) in patients with prior renal 
dysfunction plus one of the following : .. 
(i) Oliguria (urine output of less than 200 ml in the preceeding 12 
hours) despite fluid resuscitation and frusemide administration 
(ii) Severe acidaemia ( pH < 7 .I ) due to metabolic acidosis 
(iii) Hyperkalaemia ( plasma K > 6.5 mmol!L ) 
(iv) Suspected uraemic organ involvement ( pericarditis,encephalopathy) 
• 
• 
Exclusion Criteria 
1. Age< 13 
2. Pregnant patients . 
3. End stage renal failure patients- patients on chronic dialysis or calculated 
creatinine clearance < I 0 mls/min 
4. The presence of more than 3 major organ failures at study recruitment 
5. Systolic blood pressure of< 90 mm Hg at study recruitment despite 
ionotropic support 
Study Protocol 
-Approval from the ·Ministry of Health Ethical Committee and Universiti Sains Malaysia 
Ethical Committee were obtained prior to the study. Informed consent was taken from 
legally authorized people (patients' close relatives i.e. parents, children of patients' 
aged> 21 years old, siblings or spouses). The study population included adult patients 
who were critically ill and on ventilatory support in ICU/CCU with acute renal failure 
(as defined earlier). Patients were randomized to receive either CVVH or CVVHD 
At enrolment, the following were recorded: -patients' demographic data, underlying 
clinical disorder, background medical history and simplified Acute Physiological 
Scoring II (SAPS II) . Urine volume & the following biochemical variables : renal 
profile (RP), arterial blood gases (ABO), full blood count (FBC) activated clotting time 
(ACT) and liver function test (LFT) were recorded at study enrolment & daily while 
patients were on treatment as well as on the day of discharge from ICU/CCU. Blood . 
were collected for cytokine analysis from patients in both groups at 0 hour and 24 hours 
of treatment with CVVH or CVVHD. CVVH and CVVHD were performed using 
standard techniques14• All treatment were performed using a 0.6 m2 AN 69 
hemofilter (Hospal Multiflow 60) and Prisma (predilution) machine. Vascular access 
• 
was achieved through the use of double-lumen central venous catheters inserted into the 
internal jugular, subclavian or femoral veins. Blood flow was adjusted to deliver a 
minimum of 120 mVmin using a rotary blood pump. For CVVH, ultrafiltrate 
was replaced intravenously with sterile bicarbonate buffered solutions to achieve an 
ultrafiltrate of2L/hour. For CVVHD, the dialysate outflow rate was set at 1.7L/hour (so 
as to achieve an equivalent urea clearance rate of 28.5 mVhour as achieved by CVVH 
of2L/hour)' 13 Hemofilters were changed every 24 hours. Anticoagulation was achieved 
using heparin bolus of 1000 U followed by an infusion rate adjusted to maintain the 
activated clothing time (ACT) between 150 to 200 sec or activated partial 
thromboplastin time ( A.P.T.T.) 2-3 times that of control. CVVH and CVVHD were 
performed without anticoagulation if heparin administration is contraindicated. Blood 
for cytokine analysis were drawn into pyrogenfree heparinised vials chilled 
immediately. Plasma was separated by centrifugation within 1 hour of collection. 
Aliquot of 250 J.lL was frozen at -70°C until used for each assay to avoid multiple 
freezing and thawing. Interleukin (IL )-6 and 1NF -a. were measured by enzyme - linked 
immunosorbent assay (ELISA) according to manufacturer's instruction. Cytokines were 
assayed in duplicate. An intrameasurement variability of <1 0% is considered 
acceptable, results outside these limits were repeated. Each set of assays were checked 
against known standards. The primary outcome measures were survival at discharge 
from ICU and the recovery of renal function at discharge from ICU which is classified 
into:-
i) 
ii) 
Full Recovery -
Partial recovery-
Restoration of concentration of serum creatinine 
and blood urea + diuresis 
Restoration of diuresis and patients no longer 
requiring renal replacement ,but with serum 
creatinine and blood urea remaining abnormal 
• 
• 
, 
~ iii) No recovery- Requirement for further renal replacement therapy 
after discontinuation of CRRT. 
The duration of the study was 28 months. Patients' duration of survival in ICU/CCU 
was calculated in days. The percentage change in interleukin (IL) - 6 and TNF -a was 
calculated from 24 hours value as compared to baseline value at 0 hours. 
STATISTICAL ANALYSIS 
Analysis was done by intention to treat, according to the randomized modality 
of CRRT treatment. Calculation of sample size was based on the percentage difference 
of36% in cytokine levels between the two modalities oftreatment.15 Power of the test 
was set at so·% with the ratio of the two modalities at 1: 1. 
Statistical analysis was done by comparing proportions of death (dichotomous 
outcome), renal recovery (ordinal outcome) and duration of survival (survival time) . 
Univariate analysis (Fisher's Exact test and Mann-Whitney U test) were applied to 
identify significant differences between the two modalities of treatment. Data was 
expressed as median (interquartile range) or percentage where appropriate. Level of 
significant (p) is taken at less than 0.05. SPSS version 11.5 was used for data entry and 
analysis. 
• 
• 
... 
RESULTS 
Over a period of 28 months (September 2001 till December 2003), a total of 20 
patients with acute renal failure (ARF) who required continuous renal replacement 
therapy (CRRT) in ICU were included in the study. The demographic and clinical 
features for patients treated with either CVVH or CVVHD are listed in Table 1. 
Table 1 : Demographic and clinical characteristics of acute renal failure patients 
treated with CVVH and CVVHD. 
CVVH CVVHD z ,;c+ p 
(n=9) (n=11) 
Age (years) 52.0(26.50) 49 .0(36.00) -0.61 0.54 
Sex(% male) 55.6% 63.6% 
- 1.00 .. 
Primary service 
-medical 88.8% 54.6% 
- -
-surgical 11.2% 45.4% - -
Sepsis 88.8% 90.9% - 1.00 
Co-morbidity 
-diabetes 55.6% 45.5% - -
-hypertension 22.2% 27.2% - -
-liver disease 0 0 - -
-heart disease 22.2% 9.1% -
-
SAPS II Score 65.1(15.50) 66.5(11.00) -0.96 0.34 
CRRT duration 47.0(123.50) 45.0(52.00) -0.15 0.88 
(hours) 
Data expres~ed as median(interq~art~le range) or number (per cent) where appropriate. 
*Mann Whitney U test, p<0.05 significant at 95% confidence interval. 
+Fisher Exact test, p<0.05 significant at 95% confidence interval. 
The age, sex, SAPS II score and duration of CRRT treatment were comparable 
between the two groups. In terms of primary service, about half of the patients treated 
with CVVHD were surgical cases and majority of cases treated with CVVH were 
• medical cases. Eighteen patients (90%) had sepsis and this was equally distributed 
between the 2 groups of treatment. The laboratory data and vital signs for patients 
treated with CVVH and CVVHD are shown in Table 2. 
Table 2: Comparison of laboratory data and vital signs for CVVH 
and CVVHD cases 
CVVH CVVHD z p* 
(n=9) (n=11) 
Blood urea (mmol/L) 19.0(7.40) 19.4(9.40) -0.99 0.32 
Serum creat (J.tmol/L) 288.6(169.62) 242.2(194.67) -1.10 0.27 
Serum albumin (g/dL) 23.4(7.20) 20.0(3.50) -1.22 0.22 
• Total bilirubin (mmol/L) 17.6(30.17) 74.0(62.50) -1.94 0.05 
Serum bicarbonate (mmoi/L) 19.8(4.162) 15.4(10.86) -1.86 0.06 
Haemoglobin (g/dL) 9.5(2.18) 10.2(2.60) -0.34 0.73 
White blood count (x10~/L) 11.7(10.06) 18.3(7.64) -1.18 0.24 
Platelets (x10~/L) 176.4(150.85) 69.0(153.38) -0.99 0.32 
Systolic blood pressure (mmHg) 117.4(22.97) 112.7(41.63) -0.72 0.47 
Urine volume (ml) 590.3(1095.00) 77.4(405.17) -1.22 0.23 
Data expressed as median(interquartile range) 
*Mann Whitney U test, p<0.05 significant at 95% confidence interval. 
• 
• 
! 
• 
Patients treated with CVVHD had lower median urine volume, higher serum 
bilirubin, higher total white blood count and lower platelet counts compared to patients 
on CVVH. However these differences were not statistically significant. 
In terms of the percentage change in the serum level of two inflammatory 
cytokines, TNF-a and IL-6, a complete set of cytokine assay (at 0 and 24 hours) were 
only obtained in three patients. In two patients who received CVVHD treatment, the 
average rise in 1NF-a. was 173.0% and the average drop in IL-6 was 18.75%. For the 
one patient treated with CVVH, TNF-a rose by 35.6% and IL-6 drop by 48.8%. The 
outcome of patients treated with CVVH and CVVHD are demonstrated in Table 3. 
Table 3-: - Comparison of outcome for CVVH versus CVVHD cases 
CVVH CVVHD z *+ p 
(n=9) (n-11) 
Survival in ICU (days) 16.0(14.00) 8.0(12.00) -1.40 0.16 
Complete Renal Recovery 11.1% 9.1% - 1.00 
Death 77.7% 90.9% - 0.57 
Data expressed as median (interquartile range) or number (per cent) where appropriate. 
* Mann Whitney U test, p<0.05 significant at 95% confidence interval. 
+Fisher Exact test, p<0.05 significant at 95% confidence interval 
Regardless of clinical characteristics or co-morbidity, the overall mortality rate 
for all patients in the study during hospitalization in ICU was 85%. However the 
differences in length of ICU stay, renal recovery and death rates between the two 
treatment groups were not statistically significant. In the CVVH treatment group, three 
patients (30%) had partial renal recovery compared to no patients (0%) in the CVVHD 
treated group. 
• 
• 
.. 
DISCUSSION 
Acute renal failure (ARF) necessitating renal replacement therapy is common in 
intensive care units (ICUs). The condition generally occurs in the course of multiorgan 
failure and is associated with a poor prognosis.2•16 Mortality rates range between 50% 
and 80%.12•17 Overall, the mortality rate for ARF patients treated with CRRT in ICU in 
this study (85%) is somewhat more dismal than that reported elsewhere. This high 
mortality may be explained by the pre- selection of patients who required CRRT i.e. 
more seriously ill patients who may not b.e suitable to undergo intermittent 
haemodialysis or peritoneal dialysis. A high percentage of septic patients in this study 
(90%) may also contribute to this overall high mortality .. Sepsis is known as an 
independent risk factor for poor outcome, it is associated with a high in-hospital 
mortality rate that dramatically increases when ARF superimposes.18•19 
The continuous renal replacement therapies (CRRT) comprise a spectrum of 
treatments that include both haemofiltration (convection-based solute and water 
removal) and haemodialysis (diffusion-based solute removal) techniques. These 
techniques have gained favour in the treatment of critically ill patients with renal failure 
primarily because of improved haemodynamic stability as compared to intermittent 
haemodialysis. Although some investigators have suggested that the use of CRRT is 
associated with improved outcomes in acute renal failure, this has not yet been 
demonstrated by prospective randomized trials.20 
In terms of comparing the outcome for patients treated with continuous 
haemofiltration or continuous haemodialysis, there are still no data on the clinical 
implications of the differences in solute removal between these two modalities. 
In this study, it was noted that in the CVVHD treated group, there were more 
surgical cases and the laboratory data appears to be less favourable (though not 
• 
.. 
statistically significant). However all the three outcomes (ICU stay, renal recovery and 
death rates) were not significantly different between the two treatment groups. This 
may suggest that patients treated with diffusive technique (CVVHD) had a similar 
clinical outcome despite the confounding factors. 
Unfortunately, the sample size in this study was too small to make strong 
conclusion on the outcome of treatment modality. This was due to the difficulty in 
choosing patients who fulfilled the inclusion criteria and there was also problem of 
getting consent from patient's relatives. Bearing this limitation in mind, the apparent 
mortality effect by treatment choice may be attributable largely to the patient's clinical 
status and not specific to the type of renal replacement therapy modality itself. 
In terms-of cytokines removal by the CRRT, our data was too limited to make 
any conclusion. However our results show that patients treated with CVVH seem to 
have more favourable outcome in terms of rate of accumulation or removal of TNF-a 
and IL-6. Tumour Necrosis Factor-a and IL-6 were chosen in this study because these 
inflammatory cytokines have been shown to correlate with severity of 
meningococcaemia (TNF-a and IL-6) and sepsis severity score as well as with 
mortality in patients developing sepsis in the ICU (TNF-a).21 •22•23 Tumour Necrosis 
Factor-a is a cytokine produced by activated macrophages shown in experimental 
studies to be a primary mediator of the deleterious effects of endotoxin.24 
Our fmding seems to agree with the previously reported decrease in plasma 
TNF-a being more marked in patients with systemic inflammatory response syndrome 
and ARF who were treated with CVVH compared to CVVHD.15 This ability of . 
haemofiltration to remove immunomodulatory substances may lead to an improvement 
in patient outcome among those with sepsis and acute renal failure Experimental and 
preliminary human evidence suggests that large volume haemofiltration more 
effectively removes some of these immunomodulatory substances in septic or highly 
• 
catabolic patients, possibly leading to better preservation of cardiovascular 
function. 25•26• Despite this observation, a review of the literature examining the effect of 
CRRT in sepsis found that benefits with this modality remained unclear.27 
In conclusion, patients treated with CVVH had more favourable changes in 
cytokines profile but the clinical outcome (ICU stay, renal recovery and death rates) 
were similar between CVVH and CVVHD treated groups. However, due to the limited 
sample size, we were not able to demonstrate the independent effect of treatment 
modality on outcome. 
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